Record List Display Page 4 of 5

US-CL-CURRENT: 435/355; 435/69.1

Full Title Citation Front Review Classification Date Reference Company Wilder Claims KWC Draw, De

☐ 8. Document ID: US 5354677 A

L5: Entry 8 of 13

File: USPT

Oct 11, 1994

US-PAT-NO: 5354677

DOCUMENT-IDENTIFIER: US 5354677 A

TITLE: Intracellular phospholipase A.sub.2 enzyme

DATE-ISSUED: October 11, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Knopf; John L.

Acton

MA

Clark; James

Acton

on MA

US-CL-CURRENT: <u>435/198</u>; <u>435/183</u>, <u>435/187</u>, <u>435/320.1</u>, <u>435/69.7</u>, <u>530/352</u>, <u>536/23.2</u>

Full Title Citation Front Review Classification Date Reference Screens Afficiation Claims KMC Draw, De

☐ 9. Document ID: US 5342764 A

L5: Entry 9 of 13

File: USPT

Aug 30, 1994

US-PAT-NO: 5342764

DOCUMENT-IDENTIFIER: US 5342764 A

TITLE: Recombinant expression system for human anti-inflammatory phospholipase

inhibitor protein

DATE-ISSUED: August 30, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Johnson; Lorin K.

Pleasanton

CA

Longenecker; John P.

Mountain View

CA

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 536/23.5

Full Title Citation Front Review Classification Date Reference Schools (Attachments) Claims KMC Draw De

☐ 10. Document ID: US 5322776 A

L5: Entry 10 of 13

File: USPT

Jun 21, 1994

Record List Display Page 5 of 5

US-PAT-NO: 5322776

DOCUMENT-IDENTIFIER: US 5322776 A

TITLE: DNA sequences encoding phospholipase A.sub.2 enzyme and processes for

producing enzyme

DATE-ISSUED: June 21, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Knopf; John L.

Acton

MA MA

Clark; James

Acton

US-CL-CURRENT: $\frac{435}{69.1}$; $\frac{435}{183}$, $\frac{435}{320.1}$, $\frac{435}{348}$, $\frac{435}{365}$, $\frac{536}{23.1}$, $\frac{536}{23.2}$, $\frac{536}{23.5}$

Full	Title	Citation	Front	Review	Classification	Date	Reference	MARIA EN PARTA	a and a second	Claims	KWIC	Draw, De
Clear		Gener	ate Col	lection	Print:	F	wd Refs	Bkw	d Refs	Gene	ate OA	ACS 🎉
	Terr	ns							Docume	ents		
	human phospholipase and DNA.clm.										13	

Display Format: CIT Change Format

Previous Page

Next Page

Go to Doc#

First Hit Fwd Refs

Previous Doc Go to Doc# Next Doc

> Print Generate Collection

L5: Entry 8 of 13

File: USPT

Oct 11, 1994

US-PAT-NO: 5354677

DOCUMENT-IDENTIFIER: US 5354677 A

TITLE: Intracellular phospholipase A.sub.2 enzyme

DATE-ISSUED: October 11, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Knopf; John L.

Acton

MA

Clark; James

Acton

MΑ

US-CL-CURRENT: 435/198; 435/183, 435/187, 435/320.1, 435/69.7, 530/352, 536/23.2

CLAIMS:

What is claimed is:

- 1. A purified homogeneous human phospholipase A.sub.2 enzyme characterized by an apparent molecular weight of approximately 110 kD under reducing conditions as determined by SDS-PAGE.
- 2. The enzyme according to claim 1, wherein said enzyme being characterized by an amino acid sequence set forth in Table I.
- 3. The enzyme according to claim 1 having one or more of the characteristics selected from the group consisting of:
- (1) enzymatic activity in an mixed micelle assay with a specific activity of 20 .mu.mol/min/mg;
- (2) resistance to DTT reducing conditions.
- 4. The enzyme according to claim 1 produced by culturing a cell line transformed with a DNA sequence set forth in Table I, said DNA sequence being in operative association with a regulatory sequence capable of directing the replication and expression of said DNA sequence in said cell.

Previous Doc Next Doc Go to Doc# First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Generate Collection Print

L3: Entry 69 of 70

File: USPT

Feb 6, 2001

US-PAT-NO: 6183739

DOCUMENT-IDENTIFIER: US 6183739 B1

TITLE: Phospholipases in animal feed

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Beudeker; Robert Franciscus Den Hoorn NL Kies; Arie Karst Pijnacker NL

US-CL-CURRENT: 424/94.6; 424/442, 426/635, 435/197, 800/298

CLAIMS:

What is claimed is:

- 1. A process for improving the efficiency of a feed utilization in which an animal is fed a diet which comprises a composition comprising a feed substance and a ready-for-use phospholipase additive.
- 2. An animal feed composition comprising a feed substance for a monogastric or polygastric animal and a phospholipase additive, wherein said monogastric or polygastric animal feed composition is suitable for direct consumption, and said phospholipase additive is provided as phospholipase enzyme in an amount sufficient to enhance weight gain or feed efficiency.
- 3. The composition of claim 2 which further comprises a phospholipid.
- 4. The composition claim 3 wherein the phospholipid comprises lecithin.
- 5. The composition of claim 2 wherein the phospholipase is obtainable from a mammal, a plant or a microorganism.
- 6. The composition of claim 5 wherein the phospholipase is a porcine, bovine, murine, rat, or human phospholipase A2.
- 7. The composition of claim 2 wherein the phospholipase is obtained by expression of recombinant DNA in a host organism.
- 8. The composition of claim 7 wherein the host organism is a microorganism selected from the group consisting of bacteria, yeast, and filamentous fungi.
- 9. The composition of claim 8 wherein the microorganism is selected from the group consisting of Bacillus, Escherichia, Saccharomyces, Kluyveromyces, Hansenula, Pichia, Yarrowia, Candida, Aspergillus, Trichoderma, Penicillium,

Record Display Form Page 2 of 2

Mucor, Fusarium and Humicola.

10. The composition of claim 9 wherein the microorganism is Escherichia coli, Saccharomyces cerevisiae, Kluyveromyces lactis or Aspergillus niger.

- 11. The composition of claim 7 wherein said host organism is a plant.
- 12. The composition of claim 2 wherein at least the portion of said phospholipase is included in the composition in the form of seeds derived from a transgenic plant.
- 13. The composition of claim 3 wherein said phospholipase is present at 1,000 to 5,000,000 International Units per kg of phospholipid.
- 14. The composition of claim 2 wherein the phospholipase is present in the range of about 100-1,000 International Units per kg of feed.
- 15. A method to produce an animal feed composition for a monogastric or polygastric animal that comprises about 10 to 10,000 IU phospholipase per kg of feed and which is suitable for direct consumption, which method comprises mixing about 10 to 10,000 IU phospholipase per kg of feed substance.
- 16. The method of claim 15 which further comprises including in said feed composition at least one phospholipid.
- 17. The method of claim 15 wherein the phospholipase is produced by recombinant means.
- 18. The method of claim 17 wherein said recombinant production is effected in a transgenic plant and material from said plant is added to said feed composition.
- 19. A transgenic plant cell, plant part, or plant which is modified to be capable to produce a recombinant phospholipase.
- 20. The plant part of claim 19 which is a seed.
- 21. A method to improve the efficiency of feed utilization in an animal, which method comprises feeding said animal a feed composition that comprises a feed substance for said animal and about 10 to 10,000 IU phospholipase per kg feed, wherein said phospholipase is provided as phospholipase enzyme included in said composition as an additive and wherein said animal is a calf.
- 22. A method for promoting the growth of a monogastric or polygastric animal which method comprises feeding said monogastric or polygastric animal a feed composition that comprises a feed substance for said animal and about 10 to 10,000 IU phospholipase per kg feed, wherein said phospholipase is provided as phospholipase enzyme included in said composition as an additive and wherein said animal is a calf.

Previous Doc Next Doc Go to Doc#

Hit List

Clear Generate Collection Print Fwd Refs Bkwd Refs
Generate OACS

Search Results - Record(s) 1 through 10 of 13 returned.

☐ 1. Document ID: US 6187559 B1

L5: Entry 1 of 13

File: USPT

Feb 13, 2001

US-PAT-NO: 6187559

DOCUMENT-IDENTIFIER: US 6187559 B1

TITLE: Phospholipase D gene

DATE-ISSUED: February 13, 2001

INVENTOR - INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Steed; Paul Michael

Bridgewater

NJ

LaSala; Daniel James

Stirling

NJ

US-CL-CURRENT: 435/69.1; 435/252.1, 435/325, 435/6, 536/23.1, 536/23.2, 536/23.5

Full Title Citation Front Review Classification Date Reference Coopenies Attachnolis Claims KMC Draw De

☐ 2. Document ID: US 6183739 B1

L5: Entry 2 of 13

File: USPT

Feb 6, 2001

US-PAT-NO: 6183739

DOCUMENT-IDENTIFIER: US 6183739 B1

TITLE: Phospholipases in animal feed

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Beudeker; Robert Franciscus

Den Hoorn

NL

Kies; Arie Karst

Pijnacker

NL

US-CL-CURRENT: <u>424/94.6</u>; <u>424/442</u>, <u>426/635</u>, <u>435/197</u>, <u>800/298</u>

Full Title Citation Front Review Classification Date Reference segments Witechnicks Claims KMC Draw De

☐ 3. Document ID: US 6060302 A

L5: Entry 3 of 13

File: USPT

May 9, 2000

US-PAT-NO: 6060302

DOCUMENT-IDENTIFIER: US 6060302 A

TITLE: Human phospholipase C-.alpha. and DNA sequence encoding the same

DATE-ISSUED: May 9, 2000

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE COUNTRY

Hirano; Naoto

Hongo 7-chome, Bunkyo-ku

JP

Hirai; Hisamaru

Tokyo

JP

US-CL-CURRENT: 435/252.3; 435/196, 435/198, 435/199, 435/252.33, 435/320.1, 435/69.1, 530/350, 536/23.1, 536/23.2, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Francisco Militar minerità a	Claims	KWIC	Draw, De
			.,								

☐ 4. Document ID: US 6017530 A

L5: Entry 4 of 13

File: USPT

Jan 25, 2000

US-PAT-NO: 6017530

DOCUMENT-IDENTIFIER: US 6017530 A

TITLE: Phospholipases in animal feed

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME

CITY STATE ZIP CODE COUNTRY

Beudeker; Robert Franciscus

Den Hoorn

NL

Kies; Arie Karst

Pijnacker

NL

US-CL-CURRENT: <u>424/94.6</u>; <u>424/442</u>, <u>435/197</u>

Full Title Citation Front Review Classification Date Reference ESCURIO CLASSIFICATION CLASSIFICATION DE

☐ 5. Document ID: US 5859222 A

L5: Entry 5 of 13

File: USPT

Jan 12, 1999

US-PAT-NO: 5859222

DOCUMENT-IDENTIFIER: US 5859222 A

TITLE: Human phosphatidylcholine phospholipase D

Record List Display Page 3 of 5

DATE-ISSUED: January 12, 1999

INVENTOR - INFORMATION:

NAME

CITY STATE ZIP CODE COUNTRY

Leung; David W.

Mercer Island WA

Tompkins; Christopher K.

Bothell WA

 $\text{US-CL-CURRENT: } \underline{536}/\underline{23.2}; \ \underline{435}/\underline{198}, \ \underline{435}/\underline{252.3}, \ \underline{435}/\underline{320.1}, \ \underline{435}/\underline{4}, \ \underline{435}/\underline{69.1}, \ \underline{530}/\underline{350},$

536/23.5

Dec 2

US-PAT-NO: 5587306

DOCUMENT-IDENTIFIER: US 5587306 A

TITLE: Phospholipase C homolog

DATE-ISSUED: December 24, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Hawkins; Phillip R.

Mountain View

CA

Seilhamer; Jeffrey J.

Los Altos Hills

CA

US-CL-CURRENT: 435/198; 435/252.33, 435/320.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sentinos"	Alta this is a	Claims	KWIC	Draw, De
	7.]	Docume	nt ID:	US 55	38885 A							
L5: E	Entry	7 of 1	.3			F	File: U	SPT		Jul	23,	1996

US-PAT-NO: 5538885

DOCUMENT-IDENTIFIER: US 5538885 A

TITLE: Expression systems

DATE-ISSUED: July 23, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hollis; Melvyn	Cheshire			GB2
Needham; Maurice R. C.	Cheshire			GB2
Gooding; Clare	Cheshire			GB2
Grosveld; Franklin G.	London			GB2
Antoniou; Michael	London			GB2

WEST Search History

Hide Items	Restore	Clear	Cancel

DATE: Sunday, July 18, 2004

Hide?	Set Name	Query	Hit Count
	DB = USP	T; PLUR=YES; OP=ADJ	
	L5	human phospholipase and DNA.clm.	13
	L4	human phospholipase A2 and DNA.clm.	2
	DB=PGP	B, USPT, USOC, EPAB, JPAB, DWPI; PLUR=YES;	OP = ADJ
	L3	human phospholipase A2 and DNA.clm.	70
	L2	phospholipase A2 and DNA.clm.	291
	L1	secretary phospholipase	5

END OF SEARCH HISTORY

=> s human phospholipase A2 and dna 85 HUMAN PHOSPHOLIPASE A2 AND DNA

=> dup rem l1

PROCESSING COMPLETED FOR L1

66 DUP REM L1 (19 DUPLICATES REMOVED)

=> s 12 and secretory

4 L2 AND SECRETORY

=> d 13 1-4 ibib ab

ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2004:85984 HCAPLUS

DOCUMENT NUMBER:

140:194432

TITLE:

Human prostate cancer marker genes associated with

various metastatic stages identified by gene

profiling, and related compositions, kits, and methods

for diagnosis, prognosis and therapy Schlegel, Robert; Endege, Wilson O.

PATENT ASSIGNEE(S):

Millennium Pharmaceuticals, Inc., USA U.S. Pat. Appl. Publ., 131 pp.

SOURCE:

CODEN: USXXCO

DOCUMENT TYPE:

INVENTOR(S):

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO. DATE
	-		
US 2004009481	A1	20040115	US 2002-166883 20020611
US 2004009481	A1	20040115	US 2002-166883 20020611
PRIORITY APPLN. INFO.	:		US 2001-297285P P 20010611
			US 2002-166883 A 20020611

The invention relates to compns., kits, and methods for diagnosing, AB staging, prognosing, monitoring and treating human prostate cancers. variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer. In particular, three sets of the marker genes set, corresponding to 11617 GenBank Accession Nos. (only 2168 new submissions) and 15 SEQ IDs, are identified by transcription profiling using RNA derived from clin. samples, that were expressed at least 2-fold or greater than the normal controls. Using TNM staging approach, these markers are divided to three groups, ones can be used to det. whether prostate cancer has metastasized, or is likely to metastasize, to the liver (M stage); ones can be used to det. whether prostate cancer has metastasized, or is likely to metastasize, to the bone (M stage); and ones can be used to det. whether prostate cancer has metastasized, or is likely to metastasize, to the lymph nodes (N stage and/or M stage). invention also relates to a kit for assessing the specific type of metastatic prostate cancer, e.g., cancer that has metastasized to the liver, bone or lymph nodes. [This abstr. record is one of three records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2003:778836 HCAPLUS

DOCUMENT NUMBER:

140:1083

TITLE:

Human group IIA secretory phospholipase A2

potentiates Ca2+ influx through L-type

voltage-sensitive Ca2+ channels in cultured rat

cortical neurons

AUTHOR (S):

Yagami, Tatsurou; Ueda, Keiichi; Asakura, Kenji; Nakazato, Hitoshi; Hata, Satoshi; Kuroda, Takayuki; Sakaeda, Toshiyuki; Sakaguchi, Gaku; Itoh, Naohiro; Hashimoto, Yutaka; Hori, Yozo

Discovery Research Laboratories, Shionogi and Co. Ltd, CORPORATE SOURCE:

Osaka, Japan

Journal of Neurochemistry (2003), 85(3), 749-758 SOURCE:

CODEN: JONRA9; ISSN: 0022-3042

Blackwell Publishing Ltd. PUBLISHER:

Journal DOCUMENT TYPE: LANGUAGE: English

Mammalian group IIA secretory phospholipase A2 (sPLA2-IIA) generates prostaglandin D2 (PGD2) and triggers apoptosis in cortical neurons. However, mechanisms of PGD2 generation and apoptosis have not yet been established. Therefore, the authors examd. how second messengers are involved in the sPLA2-IIA-induced neuronal apoptosis in primary cultures of rat cortical neurons. The sPLA2-IIA potentiated a marked influx of Ca2+ into neurons before apoptosis. A calcium chelator and a blocker of the L-type voltage-sensitive Ca2+ channel (L-VSCC) prevented neurons from sPLA2-IIA-induced neuronal cell death in a concn.-dependent manner. Furthermore, the L-VSCC blocker ameliorated sPLA2-IIA-induced morphol. alterations and apoptotic features such as condensed chromatin and fragmented DNA. Other blockers of VSCCs such as N type and P/Q types did not affect the neurotoxicity of sPLA2-IIA. Blockers of L-VSCC significantly suppressed sPLA2-IIA-enhanced Ca2+ influx into neurons. Moreover, reactive oxygen species (ROS) were generated prior to apoptosis. Radical scavengers reduced not only ROS generation, but also the sPLA2-IIA-induced Ca2+ influx and apoptosis. In conclusion, the

involved in sPLA2-IIA-induced apoptosis in cooperation with Ca2+. 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

authors demonstrated that sPLA2-IIA potentiates the influx of Ca2+ into neurons via L-VSCC. Furthermore, the present study suggested that

eicosanoids and ROS generated during arachidonic acid oxidative metab. are

ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN L3

ACCESSION NUMBER:

2000:402010 HCAPLUS

DOCUMENT NUMBER:

133:39883

TITLE:

Cloning of cDNA for human secretory

phospholipase A2 and its use

INVENTOR(S):

Ishizaki, Jun; Suzuki, Noriko; Hanasaki, Kohji Shionogi & Co., Ltd., Japan

PATENT ASSIGNEE(S):

PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

SOURCE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
PATENT NO.
                                      APPLICATION NO. DATE
                KIND DATE
    -----
                                       -----
                                   WO 1999-JP6844 19991207
    WO 2000034486 A1 20000615
        W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
            CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
            IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
            MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
            SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                   EP 1999-957421 19991207
    EP 1143005
                   A1 20011010
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
                                     US 2001-856486 20010611
JP 1998-349608 A 19981209
                   B1 20040629
    US 6756219
PRIORITY APPLN. INFO.:
                                     WO 1999-JP6844
                                                     W 19991207
```

AB The cDNA encoding a novel human secretory phospholipase A2 (EC

3.1.1.4) has been isolated from a Marathon-ready cDNA library of human intestines. The mature enzyme is comprised of 125 amino acids. Claimed are methods of recombinant prepn. of phospholipase A2 with mammalian cell lines, antibodies to phospholipase A2, a diagnostic or therapeutic agent or an assay kit contg. the antibodies, and methods of screening the inhibitors of phospholipase A2 as well as the inhibitors.

REFERENCE COUNT:

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

10

1998:289111 HCAPLUS ACCESSION NUMBER:

129:92195 DOCUMENT NUMBER:

Bacterial expression and characterization of human TITLE:

secretory class V phospholipase A2

AUTHOR (S): Han, Sang-Kyou; Yoon, Edward T.; Cho, Wonhwa Department of Chemistry (M/C 111), University of CORPORATE SOURCE:

Illinois at Chicago, Chicago, IL, 60607-7061, USA

Biochemical Journal (1998), 331(2), 353-357 SOURCE:

CODEN: BIJOAK; ISSN: 0264-6021

Portland Press Ltd. PUBLISHER:

DOCUMENT TYPE: Journal English LANGUAGE:

Mammalian secretory class V phospholipase A2 (PLA2) is a newly discovered PLA2 that is implicated in eicosanoid formation in inflammatory cells. As a first step towards understanding the structure, function and regulation of this PLA2, we constructed a bacterial expression vector for human secretory class V PLA2 (hV-PLA2), over-expressed and purified the protein, and detd. its phys. and kinetic properties. When compared with human class IIa enzyme (hIIa-PLA2), hV-PLA2 has several distinct properties. First, hV-PLA2 can catalyze the hydrolysis of phosphatidylcholine more effectively than hIIa-PLA2 by two orders of magnitude. Secondly, hV-PLA2 has much higher binding affinity and activity for compactly packed phosphatidylcholine bilayers than hIIa-PLA2. Finally, hV-PLA2 has much reduced thermal stability compared with hIIa-PLA2. These data suggest that hV-PLA2 is better suited than hIIa-PLA2 for acting on the outer cellular membrane and liberating arachidonic acid from membrane phospholipids. Also, the unusually low thermal stability of hV-PLA2 might contribute to tighter regulation of its activities in extracellular media.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:11:23 ON 18 JUL 2004)

FILE 'MEDLINE, HCAPLUS, BIOSIS, BIOTECHDS, SCISEARCH, EMBASE' ENTERED AT 14:11:57 ON 18 JUL 2004

85 S HUMAN PHOSPHOLIPASE A2 AND DNA L166 DUP REM L1 (19 DUPLICATES REMOVED) L2

4 S L2 AND SECRETORY L3

=> log y COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 19.32 19.11 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION -2.94 CA SUBSCRIBER PRICE -2.94

STN INTERNATIONAL LOGOFF AT 14:14:03 ON 18 JUL 2004